Stonepine Capital Management’s Kezar Life Sciences KZR Stock Holding History

Stonepine Capital Management’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-156,179	Closed	-$982K	–	94
2025 Q4	$982K	Sell	156,179 -227,003	-59%	-$1.32M	0.72%	38
2025 Q3	$1.49M	Buy	383,182 +213,323	+126%	+$875K	1.21%	21
2025 Q2	$778K	Buy	169,859 +69,859	+70%	+$299K	0.76%	32
2025 Q1	$488K	Sell	100,000 -10,000	-9%	-$60.7K	0.47%	39
2024 Q4	$739K	Sell	110,000 -39,131	-26%	-$292K	0.6%	34
2024 Q3	$1.15M	Buy	149,131 +44,086	+42%	+$266K	0.73%	26
2024 Q2	$630K	Buy	+105,045	New	+$798K	0.58%	20

Other funds holding KZR

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Stonepine Capital Management's KZR Position: Q1 2026 in Review

Stonepine Capital Management sold out of Kezar Life Sciences (KZR) in Q1 2026, closing a stake of 156,179 shares — an estimated $982K sold.

Stonepine Capital Management first reported a position in KZR in Q2 2024 and held it in 7 quarters. The position peaked at $1.49M in Q3 2025. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

Stonepine Capital Management reported no remaining Kezar Life Sciences position as of Q1 2026 after selling out during the quarter.
Stonepine Capital Management sold 156,179 Kezar Life Sciences shares in Q1 2026, an estimated $982K.
Stonepine Capital Management first reported a position in Kezar Life Sciences in Q2 2024 and held it in 7 quarters.
Stonepine Capital Management's Kezar Life Sciences position peaked at $1.49M in Q3 2025.
43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.